65213-96-9

Basic information

• Product Name: 2-CHLORO-5,6-DIMETHYL-3-NITRO-PYRIDINE
• Synonyms: 2-CHLORO-5,6-DIMETHYL-3-NITRO-PYRIDINE
• CAS NO: 65213-96-9
• Molecular Formula: C₇H₇ClN₂O₂
• Molecular Weight: 186.59568
• Mol File: 65213-96-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-CHLORO-5,6-DIMETHYL-3-NITRO-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5,6-DIMETHYL-3-NITRO-PYRIDINE(65213-96-9)
• EPA Substance Registry System: 2-CHLORO-5,6-DIMETHYL-3-NITRO-PYRIDINE(65213-96-9)

Safety Data

• Hazardous Substances Data: 65213-96-9(Hazardous Substances Data)

Upstream product

• 132247-74-6 (E)-4-hydroxy-3-methylbut-3-en-2-one sodium salt 
• 72716-80-4 1,2-dihydro-5,6-dimethyl-2-oxo-3-pyridinecarbonitrile 
• 27992-31-0 5,6-dimethyl-2(1H)-pyridone 
• 98276-88-1 3-nitro-5,6-dimethyl-2(1H)-pyridinone 
• 132247-74-6 2-methyl-3-oxo-1-butene 1-oxide sodium salt 

Downstream Products

• 441304-12-7 5,6-dimethyl-3-[[ethoxy(thiocarbonyl)]thio]-2-methoxypyridine 
• 415908-32-6 2-{4-[(5,6-dimethyl-3-nitro-2-pyridinyl)amino]phenyl}ethanol 
• 61893-00-3 5,6-dimethyl-3-hydroxypyridine 
• 858338-82-6 N-[4-(3,5-dimethyl-benzyl)-2-methoxy-5,6-dimethyl-pyridin-3-yl]-2,2-dimethyl-propionamide 
• 847741-02-0 N-[2-methoxy-5,6-dimethyl-4-(3-methylbenzoyl)pyridin-3-yl]-2,2-dimethylpropionamide 
• 847741-01-9 N-[4-((3-methylphenyl)hydroxymethyl)-2-methoxy-5,6-dimethylpyridin-3-yl]-2,2-dimethylpropionamide 
• 248247-23-6 3-amino-4-(3,5-dimethyl-benzyl)-5,6-dimethyl-1H-pyridin-2-one 
• 248247-85-0 3-amino-5,6-dimethyl-4-(3-methylbenzoyl)pyridin-2(1H)-one 
• 150127-27-8 3-amino-2-chloro-5,6-dimethylpyridine 
• 66093-07-0 3-amino-5,6-dimethylpyridine 

Relevant articles and documents

4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: In vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains

In a program to optimize the anti-HIV activity of the 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 9 and 10, lead compounds in a new class of highly potent non-nucleoside type inhibitors of HIV-1 reverse transcriptase, modification of the alkyl substitutents at the C-5 and C-6 positions on the pyridinone ring and of the substitutents on the C-3 amino group has been studied. Of the 17 new 5/6-modified analogues prepared, compounds 31b and 32b substituted at C-5 by an extended nonpolar chain containing an ether function and a C-6 methyl group and compound 35 bearing a C-5 ethyl/C-6 hydroxymethyl substituent pattern were selected on the basis of their in vitro activity against wild-type HIV and the three principle mutant strains, K103N, Y181C, and Y188L. When tested further, it was shown that these molecules, and in particular compound 35, are globally more active than 9, 10, and efavirenz against an additional eight single [L100I, K101E, V106A, E138K, V179E, G190A/S, and F227C] and four double HIV mutant strains [L100I + K103N, K101E + K103N, K103N + Y181C, and F227L + V106A], which are clinically relevant. Concerning modulation of the N-3 substituent, 36 new analogues were prepared. Of these, the N-methyl-N-(2-methoxyethyl)-substituted compounds 40, 42, and 62, as well as the doubly modified compounds 77a and 77b, were selected from the initial screen and were subsequently shown to be active at sub-micromolar concentrations (IC50's) against all the other mutant strains except K103N + Y181C and F227L + V106A. Two possible, but distinct, modes of binding of these analogues in RT were suggested from molecular modeling studies. The preferred mode of binding for compound 62, corresponding to the predicted "orientation 1", was revealed in the X-ray crystal structure of the compound 62-RT complex.

PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR

It was found that the compound having a binding activity to the cannabinoid type 2 receptor represented by the formula (I): wherein R' is a group represented by the formula: -Y1-Y2-Y3Ra wherein Y1 is single bond or the like; Y2 is -C(=O)-NH- or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; R5 is optionally substituted alkyl or the like; or R3 and R4 taken together with the adjacent atom form cyclic group or the like.

A New Approach to the Synthesis Of Lavendamycin Analogues.

A three-steps approach to the lavendamycin skeleton from benzene, pyridine and quinoline blocks is described.It is based on a new synthetic methodology for the preparation of α-substituted β-carbolines which involves such reactions as Directed Ortho Metal